• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Rayner's Recently Acquired Ophteis OVD Range and What This Means for Cataract Surgery

Article

Professor Steve Arshinoff and Rayner CEO Tim Clover announce Rayner's recent acquisition of the Ophteis OVD range at the Company's celebratory event, held at the 2015 ESCRS in Barcelona.

Professor Steve Arshinoff and Rayner CEO Tim Clover announce Rayner's recent acquisition of the Ophteis OVD range at the Company's celebratory event, held at the 2015 ESCRS in Barcelona. Professor Arshinoff goes on to talk about the importance of OVDs in cataract surgery and how there is a gap in the market when it comes to innovation in this area. For more information please watch our video.

For further information on the Ophteis OVD range, please visit www.rayner.com/en/ovd 

Back to the Eye-to-Eye Innovation Series

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.